Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
NCT05341947Phase 1Withdrawn
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LuLym-T in glioblastoma (GBM). Primary endpoint: Maximum Tolerated Dose at 2 months. Planned start Jun 2026; status: withdrawn.
02
Drugs
LuLym-T
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05341947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341947.